Altamira Therapeutics Ltd. CYTOF

Company Overview

Altamira Therapeutics Ltd. is a clinical-stage biotechnology company focused on the development of RNA-based therapeutics and delivery technologies. The company operates within the biopharmaceutical and RNA therapeutics industries, with a strategic emphasis on non-viral RNA delivery platforms and intranasal administration routes. Altamira’s core value proposition centers on enabling the safe and effective delivery of RNA therapeutics to extrahepatic tissues, an area that remains a key challenge in the broader RNA drug development landscape.

The company’s primary business activities are driven by its proprietary RNA delivery platform and a limited pipeline of therapeutic candidates, rather than commercialized products. Altamira traces its origins to Auris Medical Holding Ltd., founded in 2003, which initially focused on treatments for ear, nose, and throat disorders. Following multiple clinical setbacks, the company rebranded as Altamira Therapeutics in 2021 and pivoted toward RNA delivery technologies, repositioning itself as a platform-oriented biotechnology company.